3 completed, 2 active not recruiting, 1 suspended. 6 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Active not recruiting 2, Suspended 1 |
| Phase 2 | 1 | Suspended 1 |
Follow CD20 Positive: new trials by email Literature Review of CD20 Positive trials Research Report on CD20 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab - Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Suspended | Northwestern University | 30 | 2018-11-20 | 2022-08-15 |
| Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Carboplatin, Etoposide, Ibrutinib - CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2014-09-12 | 2018-01-26 |
| Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Carboplatin, Carfilzomib, Etoposide - CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 29 | 2014-04-17 | 2026-08-26 |
| Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma Ipilimumab, Laboratory Biomarker Analysis, Rituximab - CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 32 | 2012-11-19 | 2018-04-11 |
| Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine - CD20 Positive, Chronic Lymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 60 | 2009-02-17 | 2019-06-03 |
Lymphoma, Large B-Cell, Diffuse (4) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, T-Cell (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoma (6) · Lymphoma, Non-Hodgkin (6) · Lymphoproliferative Disorders (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Lymphoma, B-Cell (4) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Leukemia (2) · Leukemia, B-Cell (2)
CT-P10 (5) · Rituximab (5) · Carboplatin (2) · Cyclophosphamide (2) · Etoposide (2) · Ifosfamide (2) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · CTLA-4 Antigen (1) · Disulfides (1) · Doxorubicin (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Immunoglobulin G (1) · Immunotherapy, Adoptive (1)
National Cancer Institute (NCI) (2) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · Roswell Park Cancer Institute (1)
United States (6)
Craig Sauter (1) · Francisco Hernandez-ILizaliturri (1) · Issa Khouri, MD (1) · Joseph Tuscano (1) · Reem Karmali, MD (1) · Sarah Larson, MD (1)
PMID 25145344, PMID 29386196, PMID 37632592, PMID 40706069
P30CA008748 (1), P30CA016672 (1), P30CA033572 (1), P30CA060553 (1), R01CA136907 (1), U01CA062505 (1), UM1CA186704 (1), UM1CA186717 (1)